A drug‐disease model for predicting survival in an Ebola outbreak

REGN‐EB3 (Inmazeb) is a cocktail of three human monoclonal antibodies approved for treatment of Ebola infection. This paper describes development of a mathematical model linking REGN‐EB3’s inhibition of Ebola virus to survival in a non‐human primate (NHP) model, and translational scaling to predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Toroghi, Masood Khaksar, Al‐Huniti, Nidal, Davis, John D., DiCioccio, A. Thomas, Rippley, Ronda, Baum, Alina, Kyratsous, Christos A., Sivapalasingam, Sumathi, Kantrowitz, Joel, Kamal, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579403/
https://www.ncbi.nlm.nih.gov/pubmed/35895082
http://dx.doi.org/10.1111/cts.13383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579403/
https://www.ncbi.nlm.nih.gov/pubmed/35895082
http://dx.doi.org/10.1111/cts.13383

Ejemplares similares